Search Results for medicines

Kashiv

Kashiv BioSciences Bolsters Leadership Team with New COO and SVP of Regulatory Affairs

Kashiv BioSciences Strengthens Executive Leadership with New Chief Operating Officer and Senior Vice President of Regulatory Affairs Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced the appointment of Viet Nguyen as Chief Operating Officer and Arlene Wolny…

Read MoreKashiv BioSciences Bolsters Leadership Team with New COO and SVP of Regulatory Affairs

Vetter Expands Global Clinical Manufacturing Network with Strategic Site Upgrades

Vetter Strengthens its Global Clinical Manufacturing Network with Strategic Site Enhancements Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), announced significant progress in the continued expansion of its global clinical manufacturing network. With the ongoing scale-up of its…

Read MoreVetter Expands Global Clinical Manufacturing Network with Strategic Site Upgrades

Dyve Biosciences and Moffitt Cancer Center Highlight Encouraging Results for Novel Topical Therapy Targeting Tumor Acidity

Dyve Biosciences and Moffitt Cancer Center Report Promising Study Results for First-of-Its-Kind Topical Therapy Targeting Tumor Acidity Dyve Biosciences, in collaboration with Moffitt Cancer Center, today reported significant study results for a first-of-its-kind investigational therapy applied to the skin and…

Read MoreDyve Biosciences and Moffitt Cancer Center Highlight Encouraging Results for Novel Topical Therapy Targeting Tumor Acidity

Genmab Reports Safety of Rina-S® Combo with Bevacizumab in Advanced Ovarian Cancer

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer Genmab A/S announced today new datademonstrating thatrinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), evaluated in…

Read MoreGenmab Reports Safety of Rina-S® Combo with Bevacizumab in Advanced Ovarian Cancer

U.S. Grants Priority Review to Ifinatamab Deruxtecan for Previously Treated ES-SCLC After Platinum Therapy

U.S. Grants Priority Review to Ifinatamab Deruxtecan for Previously Treated ES-SCLC Patients After Platinum Therapy Daiichi Sankyo and Merck & Co. have reached an important regulatory milestone with the U.S. Food and Drug Administration accepting their Biologics License Application (BLA)…

Read MoreU.S. Grants Priority Review to Ifinatamab Deruxtecan for Previously Treated ES-SCLC After Platinum Therapy

Bial Launches Education and Awareness Campaign for World Parkinson’s Day

Bial Introduces Awareness and Education Initiative in Support of World Parkinson’s Day Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, has announced the launch of a major global awareness initiative titled “Dialogues with Parkinson’s” to mark World…

Read MoreBial Launches Education and Awareness Campaign for World Parkinson’s Day

Byondis Names Christoph Korpus, PhD, MBA as Chief Executive Officer, Expanding Multimedia Integration

Byondis Names Christoph Korpus, PhD, MBA as Chief Executive Officer, Strengthening Leadership with Multimedia Announcement Byondis B.V., an independent biotechnology company focused on the development of innovative targeted therapies for cancer, has announced a significant leadership transition with the appointment…

Read MoreByondis Names Christoph Korpus, PhD, MBA as Chief Executive Officer, Expanding Multimedia Integration

CMS Assigns COVID-19–Specific HCPCS Codes for Fresenius Kabi’s Tyenne® (tocilizumab-aazg)

Fresenius Kabi Receives CMS Approval for COVID-19 Indication-Specific HCPCS Codes for Tyenne® (tocilizumab-aazg) Fresenius Kabi, a subsidiary of Fresenius and a global leader in essential medicines and medical technologies, has announced a significant reimbursement milestone for its biologic therapy Tyenne®…

Read MoreCMS Assigns COVID-19–Specific HCPCS Codes for Fresenius Kabi’s Tyenne® (tocilizumab-aazg)

Cosette Pharmaceuticals Expands Branded Portfolio with SYMPAZAN® and Other Asset Acquisition from Assertio

Cosette Pharmaceuticals Broadens Branded Portfolio with Acquisition of SYMPAZAN® and Additional Assets from Assertio Cosette Pharmaceuticals has announced the successful closing of a strategic acquisition that significantly expands its branded product portfolio and reinforces its position in key therapeutic areas.…

Read MoreCosette Pharmaceuticals Expands Branded Portfolio with SYMPAZAN® and Other Asset Acquisition from Assertio

Virica Biotech and FUJIFILM Biosciences Partner to Advance AAV Production Enhancers Under Canada–Japan Program

Virica Biotech and FUJIFILM Biosciences Team Up to Advance AAV Production Enhancers Through Canada–Japan Co-Innovation Initiative Virica Biotech, a biotechnology firm focused on improving viral vector manufacturing through its proprietary Viral Sensitizer Enhancer (VSE™) technology, has announced a new international…

Read MoreVirica Biotech and FUJIFILM Biosciences Partner to Advance AAV Production Enhancers Under Canada–Japan Program